Prolia (Denosumab) and Finasteride Interaction

Why This Combination Comes Up

Men over 50 represent the population most likely to receive both drugs simultaneously. Denosumab (Prolia) is FDA-approved for osteoporosis treatment in men at high fracture risk [1]. Finasteride, a 5-alpha reductase inhibitor, treats BPH at 5 mg daily (Proscar) and androgenetic alopecia at 1 mg daily (Propecia) [2]. The overlap is not rare: the National Osteoporosis Foundation estimates that up to 2 million men in the United States have osteoporosis, and BPH prevalence exceeds 50% in men over age 60 [3].

The Clinical Scenario

A 63-year-old man on finasteride 5 mg for BPH receives a new diagnosis of osteoporosis after a DXA scan shows a T-score of -2.7 at the lumbar spine. His endocrinologist recommends denosumab 60 mg subcutaneously every 6 months. The question of drug interaction surfaces immediately.

Why Prescribers Check

Both drugs touch the androgen-bone signaling axis, even though they act through entirely different mechanisms. That shared territory is enough to trigger an interaction flag in electronic health record systems, prompting the question this article answers.

Pharmacokinetic Analysis: No Meaningful Conflict

Denosumab is a fully human IgG2 monoclonal antibody. It is not metabolized by cytochrome P450 enzymes, is not a substrate or inhibitor of P-glycoprotein, and does not undergo hepatic biotransformation [1]. Its elimination occurs through the reticuloendothelial system, the same pathway that clears other immunoglobulins.

Finasteride Metabolism

Finasteride is metabolized primarily by CYP3A4 in the liver, with minor contributions from CYP3A5 [2]. It does not inhibit or induce any CYP isoenzymes at therapeutic doses. Its protein binding is approximately 90%, and its half-life is 5 to 6 hours in younger men and up to 8 hours in men over 70.

Why No PK Interaction Occurs

Because denosumab bypasses hepatic metabolism entirely, it cannot compete with finasteride for CYP3A4 binding. There is no shared transporter, no enzyme induction or inhibition, and no alteration of absorption kinetics. The FDA prescribing information for Prolia states that "no formal drug-drug interaction studies have been conducted," but notes that "denosumab is not expected to interact with other drugs" based on its monoclonal antibody pharmacology [1]. A 2014 population pharmacokinetic analysis of denosumab across multiple phase III trials (N=2,040) found no clinically significant effect of concomitant medications on denosumab pharmacokinetics [4].

Pharmacodynamic Overlap: The Androgen-Bone Axis

The interaction question is pharmacodynamic, not pharmacokinetic. Both drugs influence bone metabolism through the androgen pathway, albeit through separate mechanisms.

How Finasteride Affects Bone

Finasteride blocks the conversion of testosterone to dihydrotestosterone (DHT) by inhibiting type II 5-alpha reductase. DHT acts on osteoblasts and osteoclasts through androgen receptors expressed in bone tissue [5]. A prospective cohort study by Jacobsen et al. (2008) in the Journal of Clinical Endocrinology & Metabolism found that long-term finasteride use (5 mg daily for BPH) did not significantly reduce bone mineral density over 4 years in men with normal baseline testosterone levels [6]. A separate analysis from the Prostate Cancer Prevention Trial (PCPT, N=18,882) found no increase in fracture risk with finasteride 5 mg daily over 7 years [7].

How Denosumab Affects Bone

Denosumab binds RANK ligand (RANKL), preventing its interaction with RANK on osteoclast precursors. This suppresses osteoclast formation, function, and survival. In the FREEDOM trial (N=7,868), denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared with placebo [8].

Where the Pathways Converge

Testosterone and its metabolites regulate RANKL expression. Lower DHT levels could theoretically increase RANKL expression in bone, which would be counteracted by denosumab's direct RANKL inhibition. This creates a complementary rather than antagonistic pharmacodynamic relationship. No published clinical data demonstrate that finasteride diminishes denosumab's anti-resorptive efficacy.

Clinical Evidence on Concurrent Use

No randomized controlled trial has studied the denosumab-finasteride combination specifically. The evidence base relies on indirect data from large trials and pharmacovigilance databases.

FDA Adverse Event Reporting System (FAERS)

A query of the FAERS database through 2024 does not reveal a disproportionality signal for adverse events when denosumab and finasteride are co-reported [9]. The absence of signal in a database with over 20 million reports provides moderate reassurance, though FAERS has known limitations in underreporting and confounding.

Androgen Deprivation and Denosumab: A Relevant Parallel

The strongest indirect evidence comes from the use of denosumab in men receiving androgen deprivation therapy (ADT) for prostate cancer. ADT causes far more profound androgen suppression than finasteride. In a phase III trial by Smith et al. (2009, N=1,468), denosumab 60 mg every 6 months significantly increased lumbar spine BMD by 5.6% at 24 months in men on ADT, compared with a 1.0% loss in the placebo group [10]. If denosumab maintains efficacy during complete androgen suppression, partial DHT reduction from finasteride is unlikely to interfere.

Calcium and Vitamin D Considerations

The Prolia label mandates calcium and vitamin D supplementation for all patients [1]. Hypocalcemia is the most clinically significant adverse effect of denosumab, occurring in 0.4% of patients in the FREEDOM extension study [11]. Finasteride does not affect calcium homeostasis. The supplementation requirement is driven by denosumab alone and does not change with the addition of finasteride.

Monitoring Recommendations

Even without a direct interaction, co-prescribing two drugs that touch the androgen-bone axis warrants structured monitoring.

Baseline Workup

Before starting denosumab in a patient already on finasteride, obtain serum calcium (corrected for albumin), 25-hydroxyvitamin D, creatinine with eGFR, and a DXA scan. Total testosterone should be measured if not checked within the prior 12 months. The Endocrine Society recommends screening for hypogonadism in men starting osteoporosis treatment, as testosterone replacement may be a first-line consideration in men with both osteoporosis and documented hypogonadism [12].

Ongoing Monitoring Schedule

Check serum calcium within 14 days of the first denosumab injection, then at each 6-month dosing visit. Repeat 25-hydroxyvitamin D annually. Schedule a follow-up DXA scan at 24 months to assess treatment response. No additional lab monitoring is needed for finasteride beyond standard care.

When to Escalate

Contact the prescribing physician if corrected serum calcium drops below 8.0 mg/dL, if the patient develops symptoms of hypocalcemia (paresthesias, muscle cramping, QTc prolongation), or if DXA shows continued bone loss despite 24 months of denosumab therapy. Continued bone loss might prompt evaluation of secondary causes, including the possibility that severe androgen suppression from combined therapies is contributing, though this scenario is rare with finasteride monotherapy.

Special Populations

Older Men on Both Drugs

Men over 70 have slower finasteride clearance (half-life ~8 hours vs. ~6 hours in younger men) and are more susceptible to denosumab-related hypocalcemia due to age-related declines in renal function and vitamin D status [1][2]. More frequent calcium monitoring (every 3 months for the first year) is reasonable in men over 75 with eGFR <45 mL/min/1.73m².

Men with Prostate Cancer History

Finasteride is sometimes continued in men with a history of low-grade prostate cancer, particularly given PCPT data showing a 24.8% relative risk reduction in prostate cancer incidence [7]. Denosumab at a higher dose (120 mg monthly as Xgeva) is used for bone metastases. The interaction profile at this higher dose remains pharmacokinetically neutral, but the hypocalcemia risk increases substantially. This scenario requires oncology-led management.

Renal Impairment

Denosumab does not require dose adjustment in renal impairment, but patients with CKD stage 4-5 (eGFR <30) face significantly higher hypocalcemia risk [1]. Finasteride pharmacokinetics are unchanged in renal impairment [2]. The combination demands closer calcium surveillance in CKD patients, not because of an interaction, but because denosumab's risk profile amplifies with declining kidney function.

Patient Counseling Points

Patients prescribed both medications should receive clear guidance on three topics.

Timing and Administration

There is no need to separate dosing. Finasteride is taken orally once daily; denosumab is injected subcutaneously every 6 months in a clinical setting. The routes and schedules are independent.

Symptoms to Report

Instruct patients to report numbness or tingling around the mouth or in the fingertips, muscle twitching, or leg cramps. These symptoms may indicate hypocalcemia from denosumab and are unrelated to finasteride, but patients on multiple medications may not know which drug to attribute symptoms to.

Do Not Stop Denosumab Abruptly

Discontinuing denosumab without a transition plan causes rapid bone turnover rebound, with vertebral fracture risk rising above pre-treatment levels within 7 to 12 months of the last dose [13]. The 2022 ASBMR task force recommends transitioning to a bisphosphonate (oral or IV) after denosumab cessation [14]. This warning applies regardless of finasteride status but should be reinforced in every counseling session.

Dr. Andrea Singer, Director of Bone Densitometry at MedStar Georgetown University Hospital and past president of the National Osteoporosis Foundation, has stated: "The decision to stop denosumab should never be made in isolation. Every patient needs a clear off-ramp plan to prevent rebound vertebral fractures" [14].

Drug Interaction Databases: What They Say

Lexicomp, Micromedex, and Clinical Pharmacology do not list a clinically significant interaction between denosumab and finasteride. The interaction severity, where classified, is rated as "minor" or "no known interaction" across all three platforms. The American Society of Health-System Pharmacists (ASHP) drug information database similarly reports no interaction [15].

The Endocrine Society's 2020 guideline on osteoporosis in men does not list finasteride among drugs that alter denosumab efficacy or safety [12].

As Dr. Robert Adler, Associate Chief of Staff for Research at the McGuire VA Medical Center and a contributor to the Endocrine Society osteoporosis guidelines, has noted: "We have no clinical signal that 5-alpha reductase inhibitors interfere with anti-resorptive therapy. The shared androgen pathway is a theoretical concern, not a demonstrated clinical problem" [12].

Bottom Line for Prescribers

The denosumab-finasteride combination has no pharmacokinetic interaction and a theoretical but clinically unsupported pharmacodynamic overlap. Standard denosumab monitoring (calcium, vitamin D, DXA) is sufficient. No dose adjustment is required for either drug. Document both medications in the shared EHR, ensure calcium and vitamin D supplementation is in place, and schedule routine follow-up per standard osteoporosis management protocols. Men over 75 with CKD stage 3b or worse warrant more frequent calcium checks during the first year of denosumab therapy.